Evidence map›Paper›PMID 38750212›Full record

ArticleActa neuropathologica2024

Aberrant CHCHD2-associated mitochondriopathy in Kii ALS/PDC astrocytes.

Nicolas Leventoux, Satoru Morimoto, Mitsuru Ishikawa, Shiho Nakamura, Fumiko Ozawa, Reona Kobayashi, Hirotaka Watanabe, Sopak Supakul, Satoshi Okamoto, Zhi Zhou and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Establishment of a novel amyotrophic lateral sclerosis patient (Frontiers in cell and developmental biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nicolas Leventoux *Department of Physiology, Keio University School of Medicine, Tokyo, Japan.
Satoru Morimoto *Department of Physiology, Keio University School of Medicine, Tokyo, Japan.
Mitsuru IshikawaDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Shiho NakamuraDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Fumiko OzawaDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Reona KobayashiDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Hirotaka WatanabeDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Sopak SupakulDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Satoshi OkamotoDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Zhi ZhouDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Hiroya KobayashiDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Chris KatoDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Yoshifumi HirokawaDepartment of Oncologic Pathology, Mie University Graduate School of Medicine, Mie, Japan.
Ikuko AibaDepartment of Neurology, NHO, Higashinagoya National Hospital, Aichi, Japan.
Shinichi TakahashiDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Shinsuke ShibataDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan.
Masaki TakaoDepartment of Clinical Laboratory, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan.
Mari YoshidaDepartment of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.
Fumito EndoDepartment of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan.
Koji YamanakaDepartment of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan.
Yasumasa KokuboKii ALS/PDC Research Centre, Mie University Graduate School of Regional Innovation Studies, Mie, Japan. kokubo7011@gmail.com.
Hideyuki OkanoDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan. hidokano@keio.jp.ORCID 0000-0001-7482-5935

Funding

Japan Agency for Medical Research and Development JP17ek0109139Japan Agency for Medical Research and Development JP20ek0109329Japan Agency for Medical Research and Development JP20ek0109395Japan Agency for Medical Research and Development JP21wm0425009Japan Agency for Medical Research and Development JP21wm0425019Japan Agency for Medical Research and Development JP22bm0804003Japan Agency for Medical Research and Development JP22bm0804023Japan Agency for Medical Research and Development JP22gm6510006Japan Agency for Medical Research and Development JP23bm1123046Japan Agency for Medical Research and Development JP23bm1423002Japan Agency for Medical Research and Development JP23kk0305024Japanese Foundation for Research and Promotion of Endoscopy JP18KK0239Japan Society for the Promotion of Science JP15J03921Japan Society for the Promotion of Science JP15K09364Japan Society for the Promotion of Science JP17H01689Japan Society for the Promotion of Science JP17K10083Japan Society for the Promotion of Science JP18K06506Japan Society for the Promotion of Science JP18K07368Japan Society for the Promotion of Science JP18K07514Japan Society for the Promotion of Science JP18KK0239Japan Society for the Promotion of Science JP19K08002Japan Society for the Promotion of Science JP19K17002Japan Society for the Promotion of Science JP20H00485Japan Society for the Promotion of Science JP20H03567Japan Society for the Promotion of Science JP21F21410Japan Society for the Promotion of Science JP21H05273Japan Society for the Promotion of Science JP21H05278Japan Society for the Promotion of Science JP21K06417Japan Society for the Promotion of Science JP22H04923Japan Society for the Promotion of Science JP22K07500Japan Society for the Promotion of Science JP22K15736Japan Society for the Promotion of Science JP22K18388Japan Society for the Promotion of Science JP22KF0333Japan Society for the Promotion of Science JP23H02882Japan Society for the Promotion of Science JP25305030MEXT JP16H06277Research Committee of CNS Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases H29-Nanchi-Ippan-085
6 · The paper itself

Abstract

Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex (ALS/PDC), a rare and complex neurological disorder, is predominantly observed in the Western Pacific islands, including regions of Japan, Guam, and Papua. This enigmatic condition continues to capture medical attention due to affected patients displaying symptoms that parallel those seen in either classical amyotrophic lateral sclerosis (ALS) or Parkinson's disease (PD). Distinctly, postmortem examinations of the brains of affected individuals have shown the presence of α-synuclein aggregates and TDP-43, which are hallmarks of PD and classical ALS, respectively. These observations are further complicated by the detection of phosphorylated tau, accentuating the multifaceted proteinopathic nature of ALS/PDC. The etiological foundations of this disease remain undetermined, and genetic investigations have yet to provide conclusive answers. However, emerging evidence has implicated the contribution of astrocytes, pivotal cells for maintaining brain health, to neurodegenerative onset, and likely to play a significant role in the pathogenesis of ALS/PDC. Leveraging advanced induced pluripotent stem cell technology, our team cultivated multiple astrocyte lines to further investigate the Japanese variant of ALS/PDC (Kii ALS/PDC). CHCHD2 emerged as a significantly dysregulated gene when disease astrocytes were compared to healthy controls. Our analyses also revealed imbalances in the activation of specific pathways: those associated with astrocytic cilium dysfunction, known to be involved in neurodegeneration, and those related to major neurological disorders, including classical ALS and PD. Further in-depth examinations revealed abnormalities in the mitochondrial morphology and metabolic processes of the affected astrocytes. A particularly striking observation was the reduced expression of CHCHD2 in the spinal cord, motor cortex, and oculomotor nuclei of patients with Kii ALS/PDC. In summary, our findings suggest a potential reduction in the support Kii ALS/PDC astrocytes provide to neurons, emphasizing the need to explore the role of CHCHD2 in maintaining mitochondrial health and its implications for the disease.

Indexed as

Amyotrophic Lateral SclerosisAstrocytesDNA-Binding ProteinsMitochondrial ProteinsTranscription FactorsFemaleHumansMaleMitochondriaCHCHD2 protein, humanDNA-Binding ProteinsMitochondrial ProteinsTranscription FactorsAmyotrophic lateral sclerosis (ALS)AstrocyteCHCHD2Kii ALS/PDCMitochondriaParkinsonism-dementia complex (PDC)

Identifiers

PMID38750212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.